Definiens and aycan have integrated OsiriXPro and LungExpert to create a workstation that automatically quantifies lung tumor size.
Wuerzburg, Germany-based aycan's OsiriX will provide the image-viewing platform, which will be integrated with Definiens's tumor analysis and quantification software. The integrated software will create a workstation that automatically quantifies lung tumors according to RECIST (Response Evaluation Criteria In Solid Tumors) and World Health Organization (WHO) guidelines.
OsiriX is an Apple-based workstation with Class II FDA-clearance and is a Class IIb CE-labeled medical device, while Munich-based Definiens develops image-analysis software. The partners displayed their new lung tumor detection program at the 96th annual scientific meeting of the Radiologic Society of North America (RSNA).